Exclusive: Former Genentech duo reunites to push Sonoma into the clinic; Ex-Magenta commercial chief heads to Editas

Joe Arron and Mark Eisner worked together for about a decade at Genentech, with broad remits but a shared passion for interstitial lung disease. They’d go their separate ways a few years ago — Arron to 23andMe as chief scientific officer of its therapeutics push and Eisner to FibroGen, where he led the medical operations.

Then, Regeneron-partnered Sonoma Biotherapeutics came calling. When the two got word they were both looking to join the cell therapy biotech, Arron and Eisner met at Philz Coffee in Burlingame, CA. For Arron, the meeting sealed the deal — he couldn’t pass up the role if that meant working with an enthusiastic Eisner again. Arron had already been on Sonoma’s scientific advisory board, and now it was time to swap roles with science chief and co-founder Fred Ramsdell, who is retiring.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。